Check out all the on-demand sessions from the Intelligent Security Summit here.


APT Pharmaceuticals Inc. announced today that it has raised $32 million in its second round from a flock of investors led by Three Arch Partners, and including InterWest Partners, Pinnacle Ventures, Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures.

APT, headquartered in Burlingame, Calif., develops drugs to combat lung diseases. Currently, the spotlight is on a compound that could prevent lung transplant rejection. The company plans to use the $55 million brought in to date to shepherd the drug through Phase III testing.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.